Abstract: PO0149
Durability of SARS-CoV-2 Spike Antibody Levels in Dialysis Patients After COVID-19 Infection
Session Information
- COVID-19: Vaccines, Diagnosis, and Treatment
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Manley, Harold J., Dialysis Clinic Inc, Nashville, Tennessee, United States
- Hsu, Caroline M., Tufts University School of Medicine, Boston, Massachusetts, United States
- Aweh, Gideon N., Dialysis Clinic Inc, Nashville, Tennessee, United States
- Weiner, Daniel E., Tufts University School of Medicine, Boston, Massachusetts, United States
- Frament, Jill M., Dialysis Clinic Inc, Nashville, Tennessee, United States
- Ladik, Vladimir, Dialysis Clinic Inc, Nashville, Tennessee, United States
- Johnson, Doug, Dialysis Clinic Inc, Nashville, Tennessee, United States
- Lacson, Eduardo K., Dialysis Clinic Inc, Nashville, Tennessee, United States
Background
Durability of SARS-CoV-2 receptor-binding domain spike antibody (RBD s-Ab) levels among patients receiving dialysis after COVID-19 [WDE(1] is unknown[EL2] beyond 6 months. We describe the persistence (index value ≥ 1 and ≥ 2 U/L) of semi-quantitative RBD s-Ab levels in dialysis patients over 14 month period.
Methods
All maintenance dialysis patients (>18 years old) within Dialysis Clinic, Inc. 260 clinics in 28 states with COVID-19 infection history and RBD s-Ab levels determined between Jan 1 and May 23, 2021 were included. On the day of RBD s-Ab level determination, patient demographics (age, sex, race, modality, ESKD vintage) and days since COVID-19 diagnosis were determined. Patient RBD s-Ab levels obtained after COVID-19 vaccination were excluded.
Results
A total of 515 patients, mean age 62±14 years, 57% male, 46% White, 94% HD and vintage 4.6±4.4 years[EL1] ,[HJM2] had 835 RBD s-Ab levels assessed at a median of 59 days (range 0-422 days) post COVID-19 diagnosis. RBD s-Ab levels were assessed 1, 2 or ≥3 times in 64%, 18% and 18% patients, respectively. Only 32 (6.2%) patients had undetectable RBD s-Ab on the last draw. A cross sectional summary of the last available RBD s-Ab levels suggests that titers remain detectable for long duration (Figure[EL3] [HJM4] ). In patients (N=186; 36%) with multiple RBD s-Ab levels (mean 28±15; median 28 days between levels), subsequent values were higher, lower [EL5] [HJM6] or unchanged 7%, 16% and 77% of time[EL7] , respectively.
Conclusion
Most maintenance dialysis patients sampled developed SARS-CoV-2 RBD s-Ab after COVID diagnosis, and durability extends up to 14 months. Further elucidation of longitudinal RBD s-Ab values post-COVID-19 infection as well as after completing vaccination for SARS-CoV-2 is needed.